Gastroparesis

1. Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol. 2022 Aug 1;117(8):1197-220.[Abstract][Full Text]

2. Lacy BE, Tack J, Gyawali CP. AGA clinical practice update on management of medically refractory gastroparesis: expert review. Clin Gastroenterol Hepatol. 2022 Mar;20(3):491-500.[Abstract][Full Text]

3. Dong K, Yu XJ, Li B, et al. Advances in mechanisms of postsurgical gastroparesis syndrome and its diagnosis and treatment. Chin J Dig Dis. 2006;7(2):76-82.[Abstract]

4. Balaji NS, Crookes PF, Banki F, et al. A safe and noninvasive test for vagal integrity revisited. Arch Surg. 2002 Aug;137(8):954-8.[Abstract]

5. Jacob A, Pittock SJ. Gastroparesis in multiple sclerosis. Mult Scler. 2007 Jun;13(5):686.[Abstract]

6. Raghav S, Kipp D, Watson J, et al. Gastroparesis with multiple sclerosis. Mult Scler. 2006 Apr;12(2):243-4.[Abstract]

7. Moshiree B, Potter M, Talley NJ. Epidemiology and pathophysiology of gastroparesis. Gastrointest Endosc Clin N Am. 2019 Jan;29(1):1-14.[Abstract]

8. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009 Apr;136(4):1225-33.[Abstract][Full Text]

9. Ye Y, Yin Y, Huh SY, et al. Epidemiology, etiology, and treatment of gastroparesis: real-world evidence from a large US national claims database. Gastroenterology. 2022 Jan;162(1):109-21.e5.[Abstract][Full Text]

10. Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001 Sep 10;161(16):1989-96.[Abstract]

11. Maleki D, Locke GR 3rd, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000 Oct 9;160(18):2808-16.[Abstract]

12. Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001 Jul;24(7):1264-9.[Abstract]

13. Cetin K, Gungor B, Isik A, et al. The effect of pneumatic balloon dilatation on gastric emptying in patients with achalasia. Hepatogastroenterology. 2003 Dec;50(suppl 2):ccci-ii.[Abstract]

14. Benini L, Sembenini C, Salandini L, et al. Gastric emptying of realistic meals with and without gluten in patients with coeliac disease. Effect of jejunal mucosal recovery. Scand J Gastroenterol. 2001 Oct;36(10):1044-8.[Abstract]

15. Perri F, Pastore M, Zicolella A, et al. Gastric emptying of solids is delayed in celiac disease and normalizes after gluten withdrawal. Acta Paediatr. 2000 Aug;89(8):921-5.[Abstract]

16. Hasler WL. Gastroparesis: symptoms, evaluation, and treatment. Gastroenterol Clin North Am. 2007 Sep;36(3):619-47, ix.[Abstract]

17. Zipfel S, Sammet I, Rapps N, et al. Gastrointestinal disturbances in eating disorders: clinical and neurobiological aspects. Auton Neurosci. 2006 Oct 30;129(1-2):99-106.[Abstract]

18. Goetze O, Wieczorek J, Mueller T, et al. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett. 2005 Mar 3;375(3):170-3.[Abstract]

19. Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil. 2006 May;18(5):369-75.[Abstract]

20. Soykan I, Sivri B, Sarosiek I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998 Nov;43(11):2398-404.[Abstract]

21. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol. 1996 Nov;8(6):569-75.[Abstract]

22. Sridhar KR, Lange RC, Magyar L, et al. Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J Lab Clin Med. 1998 Dec;132(6):541-6.[Abstract]

23. Marie I, Levesque H, Ducrotte P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001 Jan;96(1):77-83.[Abstract]

24. Shih WJ, DeLand FH, Domstad PA, et al. Scintigraphic findings in primary amyloidosis of the heart and stomach. Clin Nucl Med. 1985 Jul;10(7):466-7.[Abstract]

25. Jonderko G, Jonderko K, Marcisz C, et al. Evaluation of gastric emptying in patients with hypothyroidism [in Polish]. Pol Arch Med Wewn. 1996 Aug;96(2):117-23.[Abstract]

26. Kahraman H, Kaya N, Demircali A, et al. Gastric emptying time in patients with primary hypothyroidism. Eur J Gastroenterol Hepatol. 1997 Sep;9(9):901-4.[Abstract]

27. Van Vlem B, Schoonjans R, Vanholder R, et al. Dyspepsia and gastric emptying in chronic renal failure patients. Clin Nephrol. 2001 Oct;56(4):302-7.[Abstract]

28. Van Vlem B, Schoonjans R, Vanholder R, et al. Delayed gastric emptying in dyspeptic chronic hemodialysis patients. Am J Kidney Dis. 2000 Nov;36(5):962-8.[Abstract]

29. Naftali T, Yishai R, Zangen T, et al. Post-infectious gastroparesis: clinical and electrogastrographic aspects. J Gastroenterol Hepatol. 2007 Sep;22(9):1423-8.[Abstract]

30. Eisenberg D. Gastroparesis and herpes. Dig Dis Sci. 1988 Aug;33(8):1050.[Abstract]

31. Navas CM, Patel NK, Lacy BE. Gastroparesis: medical and therapeutic advances. Dig Dis Sci. 2017 Sep;62(9):2231-40.[Abstract]

32. Caras S, Laurie S, Cronk W, et al. Case report: pancreatic cancer presenting with paraneoplastic gastroparesis. Am J Med Sci. 1996 Jul;312(1):34-6.[Abstract]

33. Berghmans T, Musch W, Brenez D, et al. Paraneoplastic gastroparesis [in French]. Rev Med Brux. 1993 Nov-Dec;14(9-10):275-8.[Abstract]

34. Franke A, Nakchbandi IA, Schneider A, et al. The effect of ethanol and alcoholic beverages on gastric emptying of solid meals in humans. Alcohol Alcohol. 2005 May-Jun;40(3):187-93.[Abstract]

35. Patrick A, Epstein O. Review article: gastroparesis. Aliment Pharmacol Ther. 2008 May;27(9):724-40.[Abstract][Full Text]

36. Koch KL. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and treatment. Dig Dis Sci. 1999 Jun;44(6):1061-75.[Abstract]

37. Hinder RA, Kelly KA. Human gastric pacesetter potential. Site of origin, spread, and response to gastric transection and proximal gastric vagotomy. Am J Surg. 1977 Jan;133(1):29-33.[Abstract]

38. Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology. 1986 Jul;91(1):94-9.[Abstract]

39. Houghton LA, Read NW, Heddle R, et al. Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology. 1988 Jun;94(6):1285-91.[Abstract]

40. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986 Jun;90(6):1919-25.[Abstract]

41. Forster J, Damjanov I, Lin Z, et al. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg. 2005 Jan;9(1):102-8.[Abstract]

42. Zarate N, Mearin F, Wang XY, et al. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. Gut. 2003 Jul;52(7):966-70.[Abstract]

43. Hasler WL, Soudah HC, Dulai G, et al. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology. 1995 Mar;108(3):727-36.[Abstract]

44. Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990 Nov;33(11):675-80.[Abstract]

45. Hunter RJ, Metz DC, Morris JB, et al. Gastroparesis: a potential pitfall of laparoscopic Nissen fundoplication. Am J Gastroenterol. 1996 Dec;91(12):2617-8.[Abstract]

46. Reddymasu SC, Bonino J, McCallum RW. Gastroparesis secondary to a demyelinating disease: a case series. BMC Gastroenterol. 2007 Jan 31;7:3.[Abstract]

47. Parkman, HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004 Nov;127(5):1592-622.[Abstract][Full Text]

48. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004 Oct;16(suppl 2):17-28.[Abstract]

49. Parkman HP, Trate DM, Knight LC, et al. Cholinergic effects on human gastric motility. Gut. 1999 Sep;45(3):346-54.[Abstract]

50. Foxx-Orenstein A, Camilleri M, Stephens D, et al. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut. 2003 Nov;52(11):1555-61.[Abstract]

51. Tougas G, Earnest DL, Chen Y, et al. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. Aliment Pharmacol Ther. 2005 Jul 1;22(1):59-65.[Abstract]

52. Nishiguchi S, Shiomi S, Kurooka H, et al. Randomized trial assessing gastric emptying in patients with chronic hepatitis C during interferon-alpha or -beta therapy and effect of cisapride. Dig Dis Sci. 2002 Jan;47(1):73-8.[Abstract]

53. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord. 2001 Nov;16(6):1041-7.[Abstract]

54. Young A. Inhibition of gastric emptying. Adv Pharmacol. 2005;52:99-121.[Abstract]

55. Jonderko K, Jonderko G, Golab T. Effect of calcitonin on gastric emptying and on serum insulin and gastrin concentrations after ingestion of a mixed solid-liquid meal in humans. J Clin Gastroenterol. 1990 Feb;12(1):22-8.[Abstract]

56. Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician. 2005 Jun 1;71(11):2123-8.[Abstract]

57. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 May;42(5):731-54.[Abstract][Full Text]

58. Park MI, Camilleri M. Gastroparesis: clinical update. Am J Gastroenterol. 2006 May;101(5):1129-39.[Abstract]

59. Coelho-Prabhu N, Forbes N, Thosani NC, et al; ASGE Standards of Practice Committee. Adverse events associated with EGD and EGD-related techniques. Gastrointest Endosc. 2022 Sep;96(3):389-401.e1.[Abstract][Full Text]

60. American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S231-43.[Abstract][Full Text]

61. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000 Jun;95(6):1456-62.[Abstract]

62. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008 Mar;103(3):753-63.[Abstract][Full Text]

63. Bharucha AE, Camilleri M, Veil E, et al. Comprehensive assessment of gastric emptying with a stable isotope breath test. Neurogastroenterol Motil. 2013 Jan;25(1):e60-9.[Abstract][Full Text]

64. Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011 Jan;23(1):8-23.[Abstract][Full Text]

65. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008 Jan 15;27(2):186-96.[Abstract][Full Text]

66. Lee AA, Rao S, Nguyen LA, et al. Validation of diagnostic and performance characteristics of the wireless motility capsule in patients with suspected gastroparesis. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1770-9.e2.[Abstract][Full Text]

67. Carson DA, O'Grady G, Du P, et al. Body surface mapping of the stomach: new directions for clinically evaluating gastric electrical activity. Neurogastroenterol Motil. 2021 Mar;33(3):e14048.[Abstract]

68. Schol J, Wauters L, Dickman R, et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterol J. 2021 Apr;9(3):287-306.[Abstract][Full Text]

69. Revicki DA, Rentz AM, Dubois D, et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res. 2004 May;13(4):833-44.[Abstract]

70. Namin F, Patel J, Lin Z, et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil. 2007 Mar;19(3):196-202.[Abstract]

71. Fleisher DR, Gornowicz B, Adams K, et al. Cyclic vomiting syndrome in 41 adults: the illness, the patients, and problems of management. BMC Med. 2005 Dec 21;3:20.[Abstract][Full Text]

72. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90.[Abstract]

73. Koskenpato J, Kairemo K, Korppi-Tommola T, et al. Role of gastric emptying in functional dyspepsia: a scintigraphic study of 94 subjects. Dig Dis Sci. 1998 Jun;43(6):1154-8.[Abstract]

74. Soykan I, Chen J, Kendall BJ, et al. The rumination syndrome: clinical and manometric profile, therapy, and long-term outcome. Dig Dis Sci. 1997 Sep;42(9):1866-72.[Abstract]

75. O'Brien MD, Bruce BK, Camilleri M. The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology. 1995 Apr;108(4):1024-9.[Abstract]

76. Chaum M, Shouhed D, Kim S, et al. Clinico-pathologic findings in patients with median arcuate ligament syndrome (celiac artery compression syndrome). Ann Diagn Pathol. 2021 Jun;52:151732.[Abstract]

77. Warncke ES, Gursahaney DL, Mascolo M, et al. Superior mesenteric artery syndrome: a radiographic review. Abdom Radiol (NY). 2019 Sep;44(9):3188-94.[Abstract]

78. Downes TJ, Cheruvu MS, Karunaratne TB, et al. Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction. J Clin Gastroenterol. 2018 Jul;52(6):477-89.[Abstract]

79. Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment - a systematic review. J Med Toxicol. 2017 Mar;13(1):71-87.[Abstract][Full Text]

80. Storm AC, Fishman DS, et al. American Society for Gastrointestinal Endoscopy guideline on informed consent for GI endoscopic procedures. Gastrointest Endosc. 2022 Feb;95(2):207-15.e2.[Abstract][Full Text]

81. Keller J, Bassotti G, Clarke J, et al. Expert consensus document: advances in the diagnosis and classification of gastric and intestinal motility disorders. Nat Rev Gastroenterol Hepatol. 2018 Apr 6;15(5):291-308.[Abstract][Full Text]

82. Olausson EA, Störsrud S, Grundin H, et al. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol. 2014 Mar;109(3):375-85.[Abstract]

83. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006 Apr;18(4):263-83.[Abstract]

84. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983 Sep-Oct;6(5):463-7.[Abstract]

85. Ricci DA, Saltzman MB, Meyer C, et al. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985 Feb;7(1):25-32.[Abstract]

86. European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. Jul 2013 [internet publication].[Full Text]

87. Zheng T, Camilleri M. Management of gastroparesis. Gastroenterol Hepatol (N Y). 2021 Nov;17(11):515-25.[Abstract][Full Text]

88. Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993 Jun 28;153(12):1469-75.[Abstract]

89. Shaffer D, Butterfield M, Pamer C, et al. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (2003). 2004 Nov-Dec;44(6):661-5.[Abstract]

90. Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, et al. Risk of extrapyramidal side effects comparing continuous vs. bolus intravenous metoclopramide administration: a systematic review and meta-analysis of randomised controlled trials. J Clin Nurs. 2015 Dec;24(23-24):3638-46.[Abstract]

91. Stewart JJ, Wood MJ, Wood CD, et al. Effects of motion sickness and antimotion sickness drugs on gastric function. J Clin Pharmacol. 1994 Jun;34(6):635-43.[Abstract]

92. Sawhney MS, Prakash C, Lustman PJ, et al. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci. 2007 Feb;52(2):418-24.[Abstract]

93. Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA. 2013 Dec 25;310(24):2640-9.[Abstract][Full Text]

94. Malamood M, Roberts A, Kataria R, et al. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017 Mar 30;11:1035-41.[Abstract][Full Text]

95. Camilleri M, Sanders KM. Opiates, the pylorus, and gastroparesis. Gastroenterology. 2020 Aug;159(2):414-21.[Abstract][Full Text]

96. Kim KH, Lee MS, Choi TY, et al. Acupuncture for symptomatic gastroparesis. Cochrane Database Syst Rev. 2018 Dec 18;12(12):CD009676.[Abstract][Full Text]

97. Lin Z, McElhinney C, Sarosiek I, et al. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations. Dig Dis Sci. 2005 Jul;50(7):1328-34.[Abstract]

98. Cutts TF, Luo J, Starkebaum W, et al. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil. 2005 Feb;17(1):35-43.[Abstract]

99. O'Grady G, Egbuji JU, Du P, et al. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg. 2009 Aug;33(8):1693-701.[Abstract][Full Text]

100. National Institute for Health and Care Excellence (UK). Gastroelectrical stimulation for gastroparesis. May 2014 [internet publication].[Full Text]

101. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003 Oct;98(10):2122-9.[Abstract]

102. Khashab MA, Wang AY, Cai Q. AGA Clinical practice update on gastric peroral endoscopic myotomy for gastroparesis: commentary. Gastroenterology. 2023 Jun;164(7):1329-35.e1.[Abstract][Full Text]

103. Jehangir A, Malik Z, Petrov RV, et al. EndoFLIP and pyloric dilation for gastroparesis symptoms refractory to pyloromyotomy/pyloroplasty. Dig Dis Sci. 2021 Aug;66(8):2682-90.[Abstract]

104. Bromer MQ, Friedenberg F, Miller LS, et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005 Jun;61(7):833-9.[Abstract]

105. Arts J, van Gool S, Caenepeel P, et al. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther. 2006 Aug 15;24(4):661-7.[Abstract]

106. Bai Y, Xu MJ, Yang X, et al. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. Digestion. 2010;81(1):27-34.[Abstract]

107. Kuo B, Barnes CN, Nguyen DD, et al. Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. Aliment Pharmacol Ther. 2021 May;53(10):1090-7.[Abstract]

108. Chedid V, Brandler J, Arndt K, et al. Randomised study: effects of the 5-HT(4) receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis. Aliment Pharmacol Ther. 2021 May;53(9):1010-20.[Abstract][Full Text]

109. Andrews CN, Woo M, Buresi M, et al. Prucalopride in diabetic and connective tissue disease-related gastroparesis: randomized placebo-controlled crossover pilot trial. Neurogastroenterol Motil. 2021 Jan;33(1):e13958.[Abstract]

110. Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: a randomized placebo-controlled crossover study. Am J Gastroenterol. 2019 Aug;114(8):1265-74.[Abstract]

111. Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2008 Feb;48(2):193-202.[Abstract]

112. Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2010 Oct;22(10):1069-e281.[Abstract]

113. Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care. 2013 Jan;36(1):41-8.[Abstract][Full Text]

114. McCallum RW, Lembo A, Esfandyari T, et al; TZP-102 Phase 2b Study Group. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013 Nov;25(11):e705-17.[Abstract][Full Text]

115. Lembo A, Camilleri M, McCallum R, et al; RM-131-004 Trial Group. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology. 2016 Jul;151(1):87-96.e6.[Abstract][Full Text]

116. Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013 Feb;25(2):e140-50.[Abstract]

117. Camilleri M, McCallum RW, Tack J, et al. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology. 2017 Nov;153(5):1240-50;e2.[Abstract][Full Text]

118. Hong SW, Chun J, Kim J, et al. Efficacy and safety of ghrelin agonists in patients with diabetic gastroparesis: a systematic review and meta-analysis. Gut Liver. 2020 Sep 15;14(5):589-600.[Abstract][Full Text]

119. Abell TL, Garcia LM, Wiener GJ, et al. Effect of oral CNSA-001 (sepiapterin, PTC923) on gastric accommodation in women with diabetic gastroparesis: a randomized, placebo-controlled, phase 2 trial. J Diabetes Complications. 2021 Sep;35(9):107961.[Abstract][Full Text]

120. Kuo B, Scimia C, Dukes G, et al. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D(2)/D(3) receptor antagonist, in patients with gastroparesis. Aliment Pharmacol Ther. 2021 Aug;54(3):267-80.[Abstract][Full Text]

121. Yamaguchi T, Kudou K, Okamoto H, et al. Evaluating the safety, tolerability, and disposition of trazpiroben, a D(2)/D(3) receptor antagonist: phase I single- and multiple-ascending dose studies in healthy Japanese participants. Clin Pharmacol Drug Dev. 2022 Jun;11(6):695-706.[Abstract][Full Text]

122. Whiting RL, Darpo B, Chen C, et al. Safety, pharmacokinetics, and pharmacodynamics of trazpiroben (TAK-906), a novel selective D(2)/D(3) receptor antagonist: a phase 1 randomized, placebo-controlled single- and multiple-dose escalation study in healthy participants. Clin Pharmacol Drug Dev. 2021 Aug;10(8):927-39.[Abstract][Full Text]

123. Tack J. Gastric motor disorders. Best Pract Res Clin Gastroenterol. 2007;21(4):633-44.[Abstract]

124. Lacy BE, Weiser K. Gastrointestinal motility disorders: an update. Dig Dis. 2006;24(3-4):228-42.[Abstract]

125. Thorn AR. Not just another case of nausea and vomiting: a review of postinfectious gastroparesis. J Am Acad Nurse Pract. 2010 Mar;22(3):125-33.[Abstract]

126. Soffer E, Abell T, Lin Z, et al. Review article: gastric electrical stimulation for gastroparesis - physiological foundations, technical aspects and clinical implications. Aliment Pharmacol Ther. 2009 Oct;30(7):681-94.[Abstract]